Progression after a third-generation EGFR tyrosine kinase inhibitor leaves platinum-pemetrexed chemotherapy and little else. HARMONi tested adding ivonescimab, a bispecific antibody, to that backbone.
This double-blind phase 3 trial at 114 centres across Asia, Europe and North America randomised 438 patients with stage IIIB to IV non-squamous EGFR-mutated non-small-cell lung cancer progressing after a third-generation TKI, with performance status 0 or 1, to ivonescimab 20 mg/kg or placebo, each with pemetrexed and carboplatin every three weeks. Seventy per cent of participants were Asian.
Median progression-free survival was 6.8 months (95% CI 5.7 to 7.1) with ivonescimab versus 4.4 months (4.1 to 5.5), hazard ratio 0.52 (95% CI 0.41 to 0.66, p<0.0001). Median overall survival was 16.8 months versus 14.0 months, hazard ratio 0.79 (95% CI 0.62 to 1.01) — a 2.8 month difference whose confidence interval just includes no effect.
Toxicity was manageable but not free. Grade 3-4 thrombocytopenia was 12% versus 6%, and serious treatment-related adverse events occurred in 28% versus 15% — nearly double. Treatment-related deaths were four versus five.
The honest summary is a clear progression-free survival benefit, a suggestion of survival benefit that has not yet crossed the line, and a doubling of serious adverse events. For a patient in this setting, 2.4 extra months before progression is meaningful, and the conversation should include that the serious toxicity risk roughly doubles for it. The predominantly Asian population makes the efficacy estimate more, not less, applicable to Indian practice.
- Ivonescimab plus platinum-pemetrexed extends median progression-free survival by 2.4 months after third-generation EGFR-TKI failure
- Overall survival favoured the combination but the confidence interval crosses 1.0 — do not present survival benefit as established
- Counsel on the near-doubling of serious treatment-related adverse events, from 15% to 28%
- Watch platelets specifically: grade 3-4 thrombocytopenia doubled from 6% to 12%
- Seventy per cent of participants were Asian, which strengthens applicability in this region
The statistics, in plain English
Two hazard ratios tell different stories. The progression-free survival figure, 0.52 with an interval of 0.41 to 0.66, is unambiguous. The overall survival figure, 0.79 with an interval of 0.62 to 1.01, has an upper bound sitting a hair above 1.0 — conventionally not significant, though the estimate leans towards benefit and follow-up continues. Resist reading a near-miss as a positive result. Note also that progression-free survival was assessed by blinded independent radiology review, which is the right safeguard in an open-label-prone endpoint, and that this trial is sponsored by the drug's manufacturer.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free